VHL Syndrome Clinical Trial
Official title:
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma
This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.
This open-label Phase 2 study will evaluate the efficacy and safety of belzutifan in participants with VHL disease who have at least 1 measurable RCC tumor. Belzutifan will be administered orally and treatment will be continuous. Participants will be evaluated radiologically approximately 12 weeks after initiation of treatment and every 12 weeks thereafter while continuing in the study for a minimum of 3 years and then every 24 weeks or more frequently if clinically indicated. Changes in VHL disease-associated non-RCC tumors will also be evaluated. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06391879 -
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
|
||
Recruiting |
NCT05534854 -
Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes
|
||
Recruiting |
NCT06195150 -
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
|
||
Completed |
NCT03108066 -
PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
|
Phase 2 |